Mangoceuticals, Inc. (MGRX)
NASDAQ: MGRX · Real-Time Price · USD
1.100
-0.080 (-6.78%)
At close: Dec 5, 2025, 4:00 PM EST
1.090
-0.010 (-0.91%)
After-hours: Dec 5, 2025, 7:47 PM EST
Mangoceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 0.47 | 0.62 | 0.73 | 0.01 | - |
| Revenue Growth (YoY) | -38.16% | -15.81% | 8083.16% | - | - |
| Cost of Revenue | 0.18 | 0.24 | 0.3 | 0 | - |
| Gross Profit | 0.28 | 0.38 | 0.43 | 0 | - |
| Selling, General & Admin | 6.81 | 5.54 | 6.39 | 2 | 0.07 |
| Amortization of Goodwill & Intangibles | 0.72 | 0.72 | - | - | - |
| Operating Expenses | 18.77 | 8.62 | 8.55 | 2 | 0.07 |
| Operating Income | -18.49 | -8.24 | -8.12 | -1.99 | -0.07 |
| Interest Expense | - | -0.01 | - | -0.01 | -0 |
| Interest & Investment Income | 0.37 | - | 0.01 | - | - |
| Other Non Operating Income (Expenses) | -1.57 | -0.45 | -1.1 | - | - |
| Pretax Income | -19.82 | -8.71 | -9.21 | -2 | -0.07 |
| Earnings From Continuing Operations | -19.82 | -8.71 | -9.21 | -2 | -0.07 |
| Minority Interest in Earnings | 0 | 0 | - | - | - |
| Net Income | -19.82 | -8.71 | -9.21 | -2 | -0.07 |
| Preferred Dividends & Other Adjustments | 0.95 | 0.87 | - | - | - |
| Net Income to Common | -20.77 | -9.58 | -9.21 | -2 | -0.07 |
| Shares Outstanding (Basic) | 7 | 2 | 1 | 1 | 1 |
| Shares Outstanding (Diluted) | 7 | 2 | 1 | 1 | 1 |
| Shares Change (YoY) | 334.64% | 84.23% | 49.22% | 34.98% | - |
| EPS (Basic) | -2.89 | -4.84 | -8.58 | -2.78 | - |
| EPS (Diluted) | -2.89 | -4.84 | -8.58 | -2.78 | - |
| Free Cash Flow | -5.9 | -4.86 | -7 | -1.39 | -0.07 |
| Free Cash Flow Per Share | -0.82 | -2.46 | -6.52 | -1.93 | -0.13 |
| Gross Margin | 60.61% | 61.70% | 58.99% | 54.26% | - |
| Operating Margin | -3960.04% | -1337.90% | -1109.84% | -22279.70% | - |
| Profit Margin | -4449.26% | -1555.26% | -1259.40% | -22352.11% | - |
| Free Cash Flow Margin | -1264.08% | -789.74% | -957.07% | -15545.59% | - |
| EBITDA | -16.49 | -7.51 | -8.09 | -1.99 | - |
| D&A For EBITDA | 2 | 0.73 | 0.02 | 0 | - |
| EBIT | -18.49 | -8.24 | -8.12 | -1.99 | -0.07 |
Source: S&P Capital IQ. Standard template.
Financial Sources.